Cargando…

The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells

NKG2D and DNAM-1 are two activating receptors, present on the surface of NK cells and other cells of the immune system. Their ligands – MICA, MICB, ULBP1-6 for NKG2D, PVR/CD155 and Nectin-2/CD112 for DNAM-1 – can be constitutively expressed at low levels in some normal cells, but they are more often...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cerboni, Cristina, Fionda, Cinzia, Soriani, Alessandra, Zingoni, Alessandra, Doria, Margherita, Cippitelli, Marco, Santoni, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882864/ https://www.ncbi.nlm.nih.gov/pubmed/24432022 http://dx.doi.org/10.3389/fimmu.2013.00508

Ejemplares similares

NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

NKG2D and Its Ligands: “One for All, All for One”
por: Zingoni, Alessandra, et al.
Publicado: (2018)

NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses
por: Zingoni, Alessandra, et al.
Publicado: (2013)

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma
por: Soriani, Alessandra, et al.
Publicado: (2013)

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation
por: Fionda, Cinzia, et al.
Publicado: (2015)

How Mucosal Epithelia Deal with Stress: Role of NKG2D/NKG2D Ligands during Inflammation
por: Antonangeli, Fabrizio, et al.
Publicado: (2017)

Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
por: Zingoni, Alessandra, et al.
Publicado: (2017)

NKG2D Ligand Shedding in Response to Stress: Role of ADAM10
por: Zingoni, Alessandra, et al.
Publicado: (2020)

Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition
por: Petillo, Sara, et al.
Publicado: (2021)

Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer
por: Fionda, Cinzia, et al.
Publicado: (2020)

Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing
por: Vulpis, Elisabetta, et al.
Publicado: (2023)

GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells
por: Kosta, Andrea, et al.
Publicado: (2022)

Cancer Exosomes as Conveyors of Stress-Induced Molecules: New Players in the Modulation of NK Cell Response
por: Vulpis, Elisabetta, et al.
Publicado: (2019)

MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma
por: Zingoni, Alessandra, et al.
Publicado: (2018)

Cereblon regulates NK cell cytotoxicity and migration via Rac1 activation
por: Fionda, Cinzia, et al.
Publicado: (2021)

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
por: Abruzzese, Maria Pia, et al.
Publicado: (2016)

Altered expression of ligands for the NKG2D and DNAM-1 activating receptors during HIV-1 infection
por: Vassena, Lia, et al.
Publicado: (2013)

NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells
por: Petillo, Sara, et al.
Publicado: (2023)

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D
por: Sayitoglu, Ece Canan, et al.
Publicado: (2020)

Key Role of the CD56(low)CD16(low) Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells
por: Vulpis, Elisabetta, et al.
Publicado: (2018)

Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention
por: Molfetta, Rosa, et al.
Publicado: (2019)

Doxorubicin–Mediated miR–433 Expression on Exosomes Promotes Bystander Senescence in Multiple Myeloma Cells in a DDR–Independent Manner
por: Vulpis, Elisabetta, et al.
Publicado: (2023)

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors
por: Abruzzese, Maria Pia, et al.
Publicado: (2019)

Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle‐associated MICA: Dual role in cancer immunosurveillance
por: Vulpis, Elisabetta, et al.
Publicado: (2022)

Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor
por: Mekhloufi, Abdelilah, et al.
Publicado: (2020)

NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
por: Frazao, Alexandra, et al.
Publicado: (2019)

Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4
por: Zöller, Tobias, et al.
Publicado: (2018)

Leveraging NKG2D Ligands in Immuno-Oncology
por: Fuertes, Mercedes Beatriz, et al.
Publicado: (2021)

Molecular Bases for the Regulation of NKG2D Ligands in Cancer
por: Huergo-Zapico, Leticia, et al.
Publicado: (2014)

Self or Non-Self? It Is also a Matter of RNA Recognition and Editing by ADAR1
por: Tassinari, Valentina, et al.
Publicado: (2022)

Editorial: The interaction of NKG2D and its ligands in health and diseases
por: Gaudieri, Silvana, et al.
Publicado: (2022)

Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma
por: Niu, Chao, et al.
Publicado: (2016)

NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
por: Zhang, Jinyu, et al.
Publicado: (2015)

The Biological Influence and Clinical Relevance of Polymorphism Within the NKG2D Ligands
por: Zuo, Jianmin, et al.
Publicado: (2018)

NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy
por: Schmiedel, Dominik, et al.
Publicado: (2018)

Genetic Variability of Human Cytomegalovirus Clinical Isolates Correlates With Altered Expression of Natural Killer Cell-Activating Ligands and IFN-γ
por: Galitska, Ganna, et al.
Publicado: (2021)

Role of Distinct Natural Killer Cell Subsets in Anticancer Response
por: Stabile, Helena, et al.
Publicado: (2017)

Manipulation of NKG2D Ligands by Cytomegaloviruses: Impact on Innate and Adaptive Immune Response
por: Slavuljica, Irena, et al.
Publicado: (2011)

Human NKG2D-ligands: cell biology strategies to ensure immune recognition
por: Fernández-Messina, Lola, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rla805gnhbgimod1mhnnbcumsj